

## Literaturverzeichnis

- Aboulker, J. P., and Swart, A. M. (1993). Preliminary analysis of the Concorde trial. Concorde Coordinating Committee. *Lancet* **341**(8849), 889-90.
- Ahlers, J. D., Belyakov, I. M., and Berzofsky, J. A. (2003). Cytokine, chemokine, and costimulatory molecule modulation to enhance efficacy of HIV vaccines. *Curr Mol Med* **3**(3), 285-301.
- Albert, J., Abrahamsson, B., Nagy, K., Aurelius, E., Gaines, H., Nystrom, G., and Fenyo, E. M. (1990). Rapid development of isolate-specific neutralizing antibodies after primary HIV-1 infection and consequent emergence of virus variants which resist neutralization by autologous sera. *Aids* **4**(2), 107-12.
- Aldovini, A., and Young, R. A. (1991). Humoral and cell-mediated immune responses to live recombinant BCG-HIV vaccines. *Nature* **351**(6326), 479-82.
- Alkhatib, G., Berger, E. A., Murphy, P. M., and Pease, J. E. (1997). Determinants of HIV-1 coreceptor function on CC chemokine receptor 3. Importance of both extracellular and transmembrane/cytoplasmic regions. *J Biol Chem* **272**(33), 20420-6.
- Alkhatib, G., Combadiere, C., Broder, C. C., Feng, Y., Kennedy, P. E., Murphy, P. M., and Berger, E. A. (1996). CC CKR5: a RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1. *Science* **272**(5270), 1955-8.
- Amara, R. R., Villinger, F., Altman, J. D., Lydy, S. L., O'Neil, S. P., Staprans, S. I., Montefiori, D. C., Xu, Y., Herndon, J. G., Wyatt, L. S., Candido, M. A., Kozyr, N. L., Earl, P. L., Smith, J. M., Ma, H. L., Grimm, B. D., Hulsey, M. L., McClure, H. M., McNicholl, J. M., Moss, B., and Robinson, H. L. (2002a). Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. *Vaccine* **20**(15), 1949-55.
- Amara, R. R., Villinger, F., Staprans, S. I., Altman, J. D., Montefiori, D. C., Kozyr, N. L., Xu, Y., Wyatt, L. S., Earl, P. L., Herndon, J. G., McClure, H. M., Moss, B., and Robinson, H. L. (2002b). Different patterns of immune responses but similar control of a simian-human immunodeficiency virus 89.6P mucosal challenge by modified vaccinia virus Ankara (MVA) and DNA/MVA vaccines. *J Virol* **76**(15), 7625-31.
- Appay, V., Nixon, D. F., Donahoe, S. M., Gillespie, G. M., Dong, T., King, A., Ogg, G. S., Spiegel, H. M., Conlon, C., Spina, C. A., Havlir, D. V., Richman, D. D., Waters, A., Easterbrook, P., McMichael, A. J., and Rowland-Jones, S. L. (2000). HIV-specific CD8(+) T cells produce antiviral cytokines but are impaired in cytolytic function. *J Exp Med* **192**(1), 63-75.
- Arora, V. K., Fredericksen, B. L., and Garcia, J. V. (2002). Nef: agent of cell subversion. *Microbes Infect* **4**(2), 189-99.
- Baba, T. W., Jeong, Y. S., Pennick, D., Bronson, R., Greene, M. F., and Ruprecht, R. M. (1995). Pathogenicity of live, attenuated SIV after mucosal infection of neonatal macaques. *Science* **267**(5205), 1820-5.
- Baba, T. W., Liska, V., Khimani, A. H., Ray, N. B., Dailey, P. J., Penninck, D., Bronson, R., Greene, M. F., McClure, H. M., Martin, L. N., and Ruprecht, R. M. (1999). Live attenuated, multiply deleted simian immunodeficiency virus causes AIDS in infant and adult macaques. *Nat Med* **5**(2), 194-203.
- Baier, M., Werner, A., Bannert, N., Metzner, K., and Kurth, R. (1995). HIV suppression by interleukin-16. *Nature* **378**(6557), 563.
- Barouch, D. H., Santra, S., Kuroda, M. J., Schmitz, J. E., Plishka, R., Buckler-White, A., Gaitan, A. E., Zin, R., Nam, J. H., Wyatt, L. S., Lifton, M. A., Nickerson, C. E., Moss, B., Montefiori, D. C., Hirsch, V. M., and Letvin, N. L. (2001). Reduction of simian-human immunodeficiency virus 89.6P viremia in rhesus monkeys by recombinant modified vaccinia virus Ankara vaccination. *J Virol* **75**(11), 5151-8.
- Barouch, D. H., Santra, S., Schmitz, J. E., Kuroda, M. J., Fu, T. M., Wagner, W., Bilska, M., Craiu, A., Zheng, X. X., Krivulka, G. R., Beaudry, K., Lifton, M. A., Nickerson, C. E., Trigona, W. L., Punt, K., Freed, D. C., Guan, L., Dubey, S., Casimiro, D., Simon, A., Davies, M. E., Chastain, M., Strom, T. B., Gelman, R. S., Montefiori, D. C., Lewis, M. G., Emini, E. A., Shiver, J. W., and Letvin, N. (2000). Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination. *Science* **290**(5491), 486-92.
- Barre-Sinoussi, F., Chermann, J. C., Rey, F., Nugeyre, M. T., Chamaret, S., Gruest, J., Dautet, C., Axler-Blin, C., Vezinet-Brun, F., Rouzioux, C., Rozenbaum, W., and Montagnier, L. (1983). Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). *Science* **220**(4599), 868-71.
- Berggren, R. E., Wunderlich, A., Ziegler, E., Schleicher, M., Duke, R. C., Looney, D., and Fang, F. C. (1995). HIV gp120-specific cell-mediated immune responses in mice after oral immunization with recombinant Salmonella. *J Acquir Immune Defic Syndr Hum Retrovirol* **10**(5), 489-95.
- Borrow, P., Lewicki, H., Hahn, B. H., Shaw, G. M., and Oldstone, M. B. (1994). Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. *J Virol* **68**(9), 6103-10.

- Bossi, G., Trambas, C., Booth, S., Clark, R., Stinchcombe, J., and Griffiths, G. M. (2002). The secretory synapse: the secrets of a serial killer. *Immunol Rev* **189**, 152-60.
- Bour, S., and Strebel, K. (2003). The HIV-1 Vpu protein: a multifunctional enhancer of viral particle release. *Microbes Infect* **5**(11), 1029-39.
- Boyer, J. D., Ugen, K. E., Wang, B., Agadjanyan, M., Gilbert, L., Bagarazzi, M. L., Chattergoon, M., Frost, P., Javadian, A., Williams, W. V., Refaeli, Y., Ciccarelli, R. B., McCallus, D., Coney, L., and Weiner, D. B. (1997). Protection of chimpanzees from high-dose heterologous HIV-1 challenge by DNA vaccination. *Nat Med* **3**(5), 526-32.
- Boyer, J. D., Wang, B., Ugen, K. E., Agadjanyan, M., Javadian, A., Frost, P., Dang, K., Carrano, R. A., Ciccarelli, R., Coney, L., Williams, W. V., and Weiner, D. B. (1996). In vivo protective anti-HIV immune responses in non-human primates through DNA immunization. *J Med Primatol* **25**(3), 242-50.
- Braciale, T. J., Morrison, L. A., Sweetser, M. T., Sambrook, J., Gething, M. J., and Braciale, V. L. (1987). Antigen presentation pathways to class I and class II MHC-restricted T lymphocytes. *Immunol Rev* **98**, 95-114.
- Brinchmann, J. E., Gaudernack, G., and Vartdal, F. (1990). CD8+ T cells inhibit HIV replication in naturally infected CD4+ T cells. Evidence for a soluble inhibitor. *J Immunol* **144**, 2961-2966.
- Carmichael, A., Jin, X., Sissons, P., and Borysiewicz, L. (1993). Quantitative analysis of the human immunodeficiency virus type 1 (HIV-1)-specific cytotoxic T lymphocyte (CTL) response at different stages of HIV-1 infection: differential CTL responses to HIV-1 and Epstein-Barr virus in late disease. *J Exp Med* **177**(2), 249-56.
- Check, E. (2003). AIDS vaccines: back to 'plan A'. *Nature* **424**(6943), 912-4.
- Chen, Z., Telfier, P., Gettie, A., Reed, P., Zhang, L., Ho, D. D., and Marx, P. A. (1996). Genetic characterization of new West African simian immunodeficiency virus SIVsm: geographic clustering of household-derived SIV strains with human immunodeficiency virus type 2 subtypes and genetically diverse viruses from a single feral sooty mangabey troop. *J Virol* **70**(6), 3617-27.
- Choe, H., Farzan, M., Sun, Y., Sullivan, N., Rollins, B., Ponath, P. D., Wu, L., Mackay, C. R., LaRosa, G., Newman, W., Gerard, N., Gerard, C., and Sodroski, J. (1996). The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. *Cell* **85**(7), 1135-48.
- Clapham, P. R., Blanc, D., and Weiss, R. A. (1991). Specific cell surface requirements for the infection of CD4-positive cells by human immunodeficiency virus types 1 and 2 and by Simian immunodeficiency virus. *Virology* **181**(2), 703-15.
- Clark, S. J., Saag, M. S., Decker, W. D., Campbell-Hill, S., Roberson, J. L., Veldkamp, P. J., Kappes, J. C., Hahn, B. H., and Shaw, G. M. (1991). High titers of cytopathic virus in plasma of patients with symptomatic primary HIV-1 infection. *N Engl J Med* **324**, 954-960.
- Clerici, M., Balotta, C., Trabattoni, D., Papagno, L., Ruzzante, S., Rusconi, S., Fusi, M. L., Colombo, M. C., and Galli, M. (1996). Chemokine production in HIV-seropositive long-term asymptomatic individuals. *Aids* **10**(12), 1432-3.
- Clerici, M., Barassi, C., Devito, C., Pastori, C., Piconi, S., Trabattoni, D., Longhi, R., Hinkula, J., Broliden, K., and Lopalco, L. (2002). Serum IgA of HIV-exposed uninfected individuals inhibit HIV through recognition of a region within the alpha-helix of gp41. *Aids* **16**(13), 1731-41.
- Cocchi, F., DeVico, A. L., Garzino-Demo, A., Arya, S. K., Gallo, R. C., and Lusso, P. (1995). Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells. *Science* **270**(5243), 1811-5.
- Cooper, D. A., Gold, J., Maclean, P., Donovan, B., Finlayson, R., Barnes, T. G., Michelmore, H. M., Brooke, P., and Penny, R. (1985). Acute AIDS retrovirus infection. Definition of a clinical illness associated with seroconversion. *Lancet* **1**(8428), 537-40.
- Cromwell, M. A., Veazey, R. S., Altman, J. D., Mansfield, K. G., Glickman, R., Allen, T. M., Watkins, D. I., Lackner, A. A., and Johnson, R. P. (2000). Induction of mucosal homing virus-specific CD8(+) T lymphocytes by attenuated simian immunodeficiency virus. *J Virol* **74**(18), 8762-6.
- Dalgleish, A. G., Beverley, P. C., Clapham, P. R., Crawford, D. H., Greaves, M. F., and Weiss, R. A. (1984). The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus. *Nature* **312**(5996), 763-7.
- Daniel, M. D., Kirchhoff, F., Czajak, S. C., Sehgal, P. K., and Desrosiers, R. C. (1992). Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene. *Science* **258**(5090), 1938-41.
- Deml, L., Bojak, A., Steck, S., Graf, M., Wild, J., Schirmbeck, R., Wolf, H., and Wagner, R. (2001). Multiple effects of codon usage optimization on expression and immunogenicity of DNA candidate vaccines encoding the human immunodeficiency virus type 1 Gag protein. *J Virol* **75**(22), 10991-1001.
- Devito, C., Hinkula, J., Kaul, R., Lopalco, L., Bwayo, J. J., Plummer, F., Clerici, M., and Broliden, K. (2000). Mucosal and plasma IgA from HIV-exposed seronegative individuals neutralize a primary HIV-1 isolate. *Aids* **14**(13), 1917-20.

- Doranz, B. J., Rucker, J., Yi, Y., Smyth, R. J., Samson, M., Peiper, S. C., Parmentier, M., Collman, R. G., and Doms, R. W. (1996). A dual-tropic primary HIV-1 isolate that uses fusin and the beta-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors. *Cell* **85**(7), 1149-58.
- Embretson, J., Zupancic, M., Beneke, J., Till, M., Wolinsky, S., Ribas, J. L., Burke, A., and Haase, A. T. (1993). Analysis of human immunodeficiency virus-infected tissues by amplification and in situ hybridization reveals latent and permissive infections at single-cell resolution. *Proc Natl Acad Sci U S A* **90**(1), 357-61.
- Etemad-Moghadam, B., Rhone, D., Steenbeke, T., Sun, Y., Manola, J., Gelman, R., Fanton, J. W., Racz, P., Tenner-Racz, K., Axthelm, M. K., Letvin, N. L., and Sodroski, J. (2001). Membrane-fusing capacity of the human immunodeficiency virus envelope proteins determines the efficiency of CD+ T-cell depletion in macaques infected by a simian-human immunodeficiency virus. *J Virol* **75**(12), 5646-55.
- Fauci, A. S., and Lane, H. C. (1984). Overview of clinical syndromes and immunology of AIDS. *Top Clin Nurs* **6**(2), 12-8.
- Feng, Y., Broder, C. C., Kennedy, P. E., and Berger, E. A. (1996). HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. *Science* **272**(5263), 872-7.
- Finkel, T. H., Tudor-Williams, G., Banda, N. K., Cotton, M. F., Curiel, T., Monks, C., Baba, T. W., Ruprecht, R. M., and Kupfer, A. (1995). Apoptosis occurs predominantly in bystander cells and not in productively infected cells of HIV- and SIV-infected lymph nodes. *Nat Med* **1**(2), 129-34.
- Fischl, M. A., Richman, D. D., Grieco, M. H., Gottlieb, M. S., Volberding, P. A., Laskin, O. L., Leedom, J. M., Groopman, J. E., Mildvan, D., Schooley, R. T., and et al. (1987). The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. *N Engl J Med* **317**(4), 185-91.
- Fuller, D. H., Murphey-Corb, M., Clements, J., Barnett, S., and Haynes, J. R. (1996). Induction of immunodeficiency virus-specific immune responses in rhesus monkeys following gene gun-mediated DNA vaccination. *J Med Primatol* **25**(3), 236-41.
- Fust, G., Dierich, M. P., and Hidvegi, T. (1995). Role of humoral factors in the progression of HIV disease. *Immunol Today* **16**(4), 167-9.
- Gallo, R. C., Salahuddin, S. Z., Popovic, M., Shearer, G. M., Kaplan, M., Haynes, B. F., Palker, T. J., Redfield, R., Oleske, J., Safai, B., and et al. (1984). Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS. *Science* **224**(4648), 500-3.
- Gao, F., Bailes, E., Robertson, D. L., Chen, Y., Rodenburg, C. M., Michael, S. F., Cummins, L. B., Arthur, L. O., Peeters, M., Shaw, G. M., Sharp, P. M., and Hahn, B. H. (1999). Origin of HIV-1 in the chimpanzee Pan troglodytes troglodytes. *Nature* **397**(6718), 436-41.
- Gardner, M. B., Luciw, P. A., Sawai, E. T., Marthas, M. L., Miller, C. J., McChesney, M. B., Lerche, N. W., and Pedersen, N. C. (1996). Simian retrovirus vaccines: simian retrovirus and simian immunodeficiency lentivirus. *AIDS Res Hum Retroviruses* **12**(5), 399-401.
- Gelderblom, H. R. (1991). Assembly and morphology of HIV: potential effect of structure on viral function. *Aids* **5**(6), 617-37.
- Geleziunas, R., Xu, W., Takeda, K., Ichijo, H., and Greene, W. C. (2001). HIV-1 Nef inhibits ASK1-dependent death signalling providing a potential mechanism for protecting the infected host cell. *Nature* **410**(6830), 834-8.
- Gottlieb, M. S., Schroff, R., Schanker, H. M., Weisman, J. D., Fan, P. T., Wolf, R. A., and Saxon, A. (1981). Pneumocystis carinii pneumonia and mucosal candidiasis in previously healthy homosexual men: evidence of a new acquired cellular immunodeficiency. *N Engl J Med* **305**(24), 1425-31.
- Graziosi, C., and Pantaleo, G. (1998). Analysis of virologic and immunologic events in HIV infection. *Pathobiology* **66**(3-4), 123-7.
- Greenberg, M. L., Lacey, S. F., Chen, C. H., Bolognesi, D. P., and Weinhold, K. J. (1997). Noncytolytic CD8 T cell-mediated suppression of HIV replication. *Springer Semin Immunopathol* **18**(3), 355-69.
- Greene, W. C. (1991). The molecular biology of human immunodeficiency virus type 1 infection. *N Engl J Med* **324**(5), 308-17.
- Grossman, Z., Meier-Schellersheim, M., Sousa, A. E., Victorino, R. M., and Paul, W. E. (2002). CD4+ T-cell depletion in HIV infection: are we closer to understanding the cause? *Nat Med* **8**(4), 319-23.
- Guyader, M., Emerman, M., Sonigo, P., Clavel, F., Montagnier, L., and Alizon, M. (1987). Genome organization and transactivation of the human immunodeficiency virus type 2. *Nature* **326**(6114), 662-9.
- Hahn, B. H., Shaw, G. M., De Cock, K. M., and Sharp, P. M. (2000). AIDS as a zoonosis: scientific and public health implications. *Science* **287**(5453), 607-14.
- Hanke, T. (2001). Vehicles for genetic vaccines against human immunodeficiency virus: induction of T cell-mediated immune responses. *Curr Mol Med* **1**(1), 123-35.
- Hanke, T., McMichael, A. J., Mwau, M., Wee, E. G., Ceberej, I., Patel, S., Sutton, J., Tomlinson, M., and Samuel, R. V. (2002a). Development of a DNA-MVA/HIVA vaccine for Kenya. *Vaccine* **20**(15), 1995-8.

- Hanke, T., McMichael, A. J., Samuel, R. V., Powell, L. A., McLoughlin, L., Crome, S. J., and Edlin, A. (2002b). Lack of toxicity and persistence in the mouse associated with administration of candidate DNA- and modified vaccinia virus Ankara (MVA)-based HIV vaccines for Kenya. *Vaccine* **21**(1-2), 108-14.
- Hanke, T., Samuel, R. V., Blanchard, T. J., Neumann, V. C., Allen, T. M., Boyson, J. E., Sharpe, S. A., Cook, N., Smith, G. L., Watkins, D. I., Cranage, M. P., and McMichael, A. J. (1999). Effective induction of simian immunodeficiency virus-specific cytotoxic T lymphocytes in macaques by using a multiepitope gene and DNA prime- modified vaccinia virus Ankara boost vaccination regimen. *J Virol* **73**(9), 7524-32.
- Hanke, T., Schneider, J., Gilbert, S. C., Hill, A. V., and McMichael, A. (1998). DNA multi-CTL epitope vaccines for HIV and Plasmodium falciparum: immunogenicity in mice. *Vaccine* **16**(4), 426-35.
- Haseltine, W. A. (1991). Molecular biology of the human immunodeficiency virus type 1. *Faseb J* **5**(10), 2349-60.
- Hirsch, V. M., Olmsted, R. A., Murphey-Corb, M., Purcell, R. H., and Johnson, P. R. (1989). An African primate lentivirus (SIVsm) closely related to HIV-2. *Nature* **339**(6223), 389-92.
- Ho, D. D., Neumann, A. U., Perelson, A. S., Chen, W., Leonard, J. M., and Markowitz, M. (1995). Rapid turnover of plasma virions and CD4 lymphocytes in HIV- 1 infection. *Nature* **373**(6510), 123-126.
- Hoffenbach, A., Langlade-Demoyen, P., Dadaglio, G., Vilmer, E., Michel, F., Mayaud, C., Autran, B., and Plata, F. (1989). Unusually high frequencies of HIV-specific cytotoxic T lymphocytes in humans. *J Immunol* **142**, 452-462.
- Holzammer, S., Holzngel, E., Kaul, A., Kurth, R., and Norley, S. (2001). High virus loads in naturally and experimentally SIVagm-infected African green monkeys. *Virology* **283**(2), 324-31.
- Jamieson, B. D., Yang, O. O., Hultin, L., Hausner, M. A., Hultin, P., Matud, J., Kunstman, K., Killian, S., Altman, J., Kommander, K., Korber, B., Giorgi, J., and Wolinsky, S. (2003). Epitope escape mutation and decay of human immunodeficiency virus type 1-specific CTL responses. *J Immunol* **171**(10), 5372-9.
- Javaherian, K., Langlois, A. J., McDanal, C., Ross, K. L., Eckler, L. I., Jellis, C. L., Profy, A. T., Rusche, J. R., Bolognesi, D. P., Putney, S. D., and et al. (1989). Principal neutralizing domain of the human immunodeficiency virus type 1 envelope protein. *Proc Natl Acad Sci U S A* **86**(17), 6768-72.
- Katzenstein, T. L., Pedersen, C., and Gerstoft, J. (1997). HIV quantification--how and why. *Ugeskr Laeger* **160**(1), 18-24.
- Klein, M. (2001). Current progress in the development of human immunodeficiency virus vaccines: research and clinical trials. *Vaccine* **19**(17-19), 2210-5.
- Klein, M. R., van Baalen, C. A., Holwerda, A. M., Kerkhof Garde, S. R., Bende, R. J., Keet, I. P., Eeftinck-Schattenkerk, J. K., Osterhaus, A. D., Schuitemaker, H., and Miedema, F. (1995). Kinetics of Gag-specific cytotoxic T lymphocyte responses during the clinical course of HIV-1 infection: a longitudinal analysis of rapid progressors and long-term asymptomatics. *J Exp Med* **181**(4), 1365-72.
- Koopman, G., Mortier, D., Hofman, S., Niphuis, H., Fagrouch, Z., Liljestrom, P., Norley, S., Sutter, G., and Heeney, J. (2004). Immunization of macaques against SIVmac using a triple combination of DNA priming and MVA plus alpha viral vector booster immunizations preserves CD4 T-cell numbers following infection with pathogenic SIVmac251 **in preparation**.
- Kotsopoulou, E., Kim, V. N., Kingsman, A. J., Kingsman, S. M., and Mitrophanous, K. A. (2000). A Rev-independent human immunodeficiency virus type 1 (HIV-1)-based vector that exploits a codon-optimized HIV-1 gag-pol gene. *J Virol* **74**(10), 4839-52.
- Koup, R. A., Safrit, J. T., Cao, Y., Andrews, C. A., McLeod, G., Borkowsky, W., Farthing, C., and Ho, D. D. (1994). Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. *J Virol* **68**(7), 4650-5.
- LaBonte, J. A., Patel, T., Hofmann, W., and Sodroski, J. (2000). Importance of membrane fusion mediated by human immunodeficiency virus envelope glycoproteins for lysis of primary CD4-positive T cells. *J Virol* **74**(22), 10690-8.
- Lang, W., Perkins, H., Anderson, R. E., Royce, R., Jewell, N., and Winkelstein, W., Jr. (1989). Patterns of T lymphocyte changes with human immunodeficiency virus infection: from seroconversion to the development of AIDS. *J Acquir Immune Defic Syndr* **2**(1), 63-9.
- Langlade-Demoyen, P., Ngo-Giang-Huong, N., Ferchal, F., and Oksenhendler, E. (1994). Human immunodeficiency virus (HIV) nef-specific cytotoxic T lymphocytes in noninfected heterosexual contact of HIV-infected patients. *J Clin Invest* **93**(3), 1293-7.
- Lehner, T., Wang, Y., Ping, L., Bergmeier, L., Mitchell, E., Cranage, M., Hall, G., Dennis, M., Cook, N., Doyle, C., and Jones, I. (1999). The effect of route of immunization on mucosal immunity and protection. *J Infect Dis* **179 Suppl 3**, S489-92.
- Letvin, N. L. (2002). Strategies for an HIV vaccine. *J Clin Invest* **110**(1), 15-20.
- Letvin, N. L., Daniel, M. D., Sehgal, P. K., Desrosiers, R. C., Hunt, R. D., Waldron, L. M., MacKey, J. J., Schmidt, D. K., Chalifoux, L. V., and King, N. W. (1985). Induction of AIDS-like disease in macaque monkeys with T-cell tropic retrovirus STLIV-III. *Science* **230**(4721), 71-3.

- Letvin, N. L., Montefiori, D. C., Yasutomi, Y., Perry, H. C., Davies, M. E., Lekutis, C., Alroy, M., Freed, D. C., Lord, C. I., Handt, L. K., Liu, M. A., and Shiver, J. W. (1997). Potent, protective anti-HIV immune responses generated by bimodal HIV envelope DNA plus protein vaccination. *Proc Natl Acad Sci U S A* **94**(17), 9378-83.
- Levy, J. A. (1993). HIV pathogenesis and long-term survival. *Aids* **7**(11), 1401-10.
- Lieberman, J., and Frankel, F. R. (2002). Engineered *Listeria monocytogenes* as an AIDS vaccine. *Vaccine* **20**(15), 2007-10.
- Lifson, J. D., Feinberg, M. B., Reyes, G. R., Rabin, L., Banapour, B., Chakrabarti, S., Moss, B., Wong-Staal, F., Steimer, K. S., and Engleman, E. G. (1986). Induction of CD4-dependent cell fusion by the HTLV-III/LAV envelope glycoprotein. *Nature* **323**(6090), 725-8.
- Ljunggren, K., Biberfeld, G., Jondal, M., and Fenyo, E. M. (1989). Antibody-dependent cellular cytotoxicity detects type- and strain-specific antigens among human immunodeficiency virus types 1 and 2 and simian immunodeficiency virus SIVmac isolates. *J Virol* **63**(8), 3376-81.
- Lu, M., Blacklow, S. C., and Kim, P. S. (1995). A trimeric structural domain of the HIV-1 transmembrane glycoprotein. *Nat Struct Biol* **2**(12), 1075-82.
- Lu, S., Arthos, J., Montefiori, D. C., Yasutomi, Y., Manson, K., Mustafa, F., Johnson, E., Santoro, J. C., Wissink, J., Mullins, J. I., Haynes, J. R., Letvin, N. L., Wyand, M., and Robinson, H. L. (1996). Simian immunodeficiency virus DNA vaccine trial in macaques. *J Virol* **70**(6), 3978-91.
- Luukkonen, B. G., Fenyo, E. M., and Schwartz, S. (1995). Overexpression of human immunodeficiency virus type 1 protease increases intracellular cleavage of Gag and reduces virus infectivity. *Virology* **206**(2), 854-65.
- Marin, M., Rose, K. M., Kozak, S. L., and Kabat, D. (2003). HIV-1 Vif protein binds the editing enzyme APOBEC3G and induces its degradation. *Nat Med* **9**(11), 1398-403.
- Marschang, P., Sodroski, J., Wurzner, R., and Dierich, M. P. (1995). Decay-accelerating factor (CD55) protects human immunodeficiency virus type 1 from inactivation by human complement. *Eur J Immunol* **25**(1), 285-90.
- McKeating, J. A., Gow, J., Goudsmit, J., Pearl, L. H., Mulder, C., and Weiss, R. A. (1989). Characterization of HIV-1 neutralization escape mutants. *Aids* **3**(12), 777-84.
- McMichael, A. (2003). Prospects for an AIDS vaccine. *Clin Med* **3**(3), 269-72.
- Mellors, J. W., Rinaldo, C. R., Jr., Gupta, P., White, R. M., Todd, J. A., and Kingsley, L. A. (1996). Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. *Science* **272**(5265), 1167-70.
- Meyaard, L., Otto, S. A., Jonker, R. R., Mijster, M. J., Keet, R. P., and Miedema, F. (1992). Programmed death of T cells in HIV-1 infection. *Science* **257**(5067), 217-9.
- Mitchell, W. M., Torres, J., Johnson, P. R., Hirsch, V., Yilma, T., Gardner, M. B., and Robinson, W. E., Jr. (1995). Antibodies to the putative SIV infection-enhancing domain diminish beneficial effects of an SIV gp160 vaccine in rhesus macaques. *Aids* **9**(1), 27-34.
- Modrow, S., and Falke, D. (1997). "Molekulare Virologie." Spektrum Akad. Verlag.
- Montefiori, D. C., Cornell, R. J., Zhou, J. Y., Zhou, J. T., Hirsch, V. M., and Johnson, P. R. (1994). Complement control proteins, CD46, CD55, and CD59, as common surface constituents of human and simian immunodeficiency viruses and possible targets for vaccine protection. *Virology* **205**(1), 82-92.
- Montelaro, R. C., Grund, C., Raabe, M., Woodson, B., Cook, R. F., Cook, S., and Issel, C. J. (1996). Characterization of protective and enhancing immune responses to equine infectious anemia virus resulting from experimental vaccines. *AIDS Res Hum Retroviruses* **12**(5), 413-5.
- Moore, J. P., and Nara, P. L. (1991). The role of the V3 loop of gp120 in HIV infection. *Aids* **5** Suppl 2, S21-33.
- Morrow, C. D., Park, J., and Wakefield, J. K. (1994). Viral gene products and replication of the human immunodeficiency type 1 virus. *Am J Physiol* **266**(5 Pt 1), C1135-56.
- Moss, A. R., and Bacchetti, P. (1989). Natural history of HIV infection. *Aids* **3**(2), 55-61.
- Murphey-Corb, M., Martin, L. N., Davison-Fairburn, B., Montelaro, R. C., Miller, M., West, M., Ohkawa, S., Baskin, G. B., Zhang, J. Y., Putney, S. D., Allison, A. C., and Eppstein, D. A. (1989). A formalin-inactivated whole SIV vaccine confers protection in macaques. *Science* **246**, 1293-1297.
- Mwau, M., McMichael, A. J., and Hanke, T. (2002). Design and validation of an enzyme-linked immunospot assay for use in clinical trials of candidate HIV vaccines. *AIDS Res Hum Retroviruses* **18**(9), 611-8.
- Myers, G. (1994). Molecular investigation of HIV transmission. *Ann Intern Med* **121**(11), 889-90.
- Nara, P. L., Smit, L., Dunlop, N., Hatch, W., Merges, M., Waters, D., Kelliher, J., Gallo, R. C., Fischinger, P. J., and Goudsmit, J. (1990). Emergence of viruses resistant to neutralization by V3-specific antibodies in experimental human immunodeficiency virus type 1 IIIB infection of chimpanzees. *J Virol* **64**(8), 3779-91.
- Natuk, R. J., Chanda, P. K., Lubeck, M. D., Davis, A. R., Wilhelm, J., Hjorth, R., Wade, M. S., Bhat, B. M., Mizutani, S., Lee, S., and et al. (1992). Adenovirus-human immunodeficiency virus (HIV) envelope recombinant vaccines elicit high-titered HIV-neutralizing antibodies in the dog model. *Proc Natl Acad Sci U S A* **89**(16), 7777-81.

- Natuk, R. J., Lubeck, M. D., Chanda, P. K., Chengalvala, M., Wade, M. S., Murthy, S. C., Wilhelm, J., Vernon, S. K., Dheer, S. K., Mizutani, S., and et al. (1993). Immunogenicity of recombinant human adenovirus-human immunodeficiency virus vaccines in chimpanzees. *AIDS Res Hum Retroviruses* **9**(5), 395-404.
- Negri, D. R., Baroncelli, S., Catone, S., Comini, A., Michelini, Z., Maggiorella, M. T., Sernicola, L., Crostarosa, F., Belli, R., Mancini, M. G., Farcomeni, S., Fagrouch, Z., Ciccozzi, M., Boros, S., Liljestrom, P., Norley, S., Heeney, J., and Titti, F. (2004). Protective efficacy of a multicomponent vector vaccine in cynomolgus monkeys after intrarectal SIVmac251 challenge. *Journal Of General Virology* **in press**.
- Negrone, M., and Buc, H. (2000). Copy-choice recombination by reverse transcriptases: reshuffling of genetic markers mediated by RNA chaperones. *Proc Natl Acad Sci U S A* **97**(12), 6385-90.
- Nilsson, C., Makitalo, B., Berglund, P., Bex, F., Liljestrom, P., Sutter, G., Erfle, V., ten Haaf, P., Heeney, J., Biberfeld, G., and Thorstensson, R. (2001). Enhanced simian immunodeficiency virus-specific immune responses in macaques induced by priming with recombinant Sembali Forest virus and boosting with modified vaccinia virus Ankara. *Vaccine* **19**(25-26), 3526-36.
- Norley, S., Beer, B., Konig, H., Jensen, F., and Kurth, R. (1998). SIVmac vaccine studies using whole inactivated virus antigen sequentially depleted of viral proteins. *J Med Primatol* **27**(4), 184-92.
- Norley, S. G., Mikschy, U., Werner, A., Staszewski, S., Helm, E. B., and Kurth, R. (1990). Demonstration of cross-reactive antibodies able to elicit lysis of both HIV-1- and HIV-2-infected cells. *J Immunol* **145**(6), 1700-5.
- Norley, S. G., Vogel, T., and Kurth, R. (1993). Anti-HIV vaccines. Current status and future developments. *Drugs* **46**(6), 947-60.
- O'Brien, T. R., Blattner, W. A., Waters, D., Eyster, E., Hilgartner, M. W., Cohen, A. R., Luban, N., Hatzakis, A., Aledort, L. M., Rosenberg, P. S., Miley, W. J., Kroner, B. L., and Goedert, J. J. (1996). Serum HIV-1 RNA levels and time to development of AIDS in the Multicenter Hemophilia Cohort Study. *Jama* **276**(2), 105-10.
- Palker, T. J., Clark, M. E., Langlois, A. J., Matthews, T. J., Weinhold, K. J., Randall, R. R., Bolognesi, D. P., and Haynes, B. F. (1988). Type-specific neutralization of the human immunodeficiency virus with antibodies to env-encoded synthetic peptides. *Proc Natl Acad Sci U S A* **85**(6), 1932-6.
- Pantaleo, G., Cohen, O. J., Schacker, T., Vaccarezza, M., Graziosi, C., Rizzardi, G. P., Kahn, J., Fox, C. H., Schnittman, S. M., Schwartz, D. H., Corey, L., and Fauci, A. S. (1998). Evolutionary pattern of human immunodeficiency virus (HIV) replication and distribution in lymph nodes following primary infection: implications for antiviral therapy. *Nat Med* **4**(3), 341-5.
- Pantaleo, G., Graziosi, C., and Fauci, A. S. (1993). The role of lymphoid organs in the pathogenesis of HIV infection. *Semin Immunol* **5**(3), 157-63.
- Peeters, M., Courgnaud, V., Abela, B., Auzel, P., Pourrut, X., Bibollet-Ruche, F., Loul, S., Liegeois, F., Butel, C., Koulagna, D., Mpoudi-Ngole, E., Shaw, G. M., Hahn, B. H., and Delaporte, E. (2002). Risk to human health from a plethora of simian immunodeficiency viruses in primate bushmeat. *Emerg Infect Dis* **8**(5), 451-7.
- Perrin, L., Kaiser, L., and Yerly, S. (2003). Travel and the spread of HIV-1 genetic variants. *Lancet Infect Dis* **3**(1), 22-7.
- Pinto, L. A., Sullivan, J., Berzofsky, J. A., Clerici, M., Kessler, H. A., Landay, A. L., and Shearer, G. M. (1995). ENV-specific cytotoxic T lymphocyte responses in HIV seronegative health care workers occupationally exposed to HIV-contaminated body fluids. *Journal of Clinical Investigation* **96**(2), 867-876.
- Popov, S., Rexach, M., Zybarth, G., Reiling, N., Lee, M. A., Ratner, L., Lane, C. M., Moore, M. S., Blobel, G., and Bukrinsky, M. (1998). Viral protein R regulates nuclear import of the HIV-1 pre-integration complex. *Embo J* **17**(4), 909-17.
- Popovic, M., Sarngadharan, M. G., Read, E., and Gallo, R. C. (1984). Detection, isolation, and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS. *Science* **224**(4648), 497-500.
- Preston, B. D., Poiesz, B. J., and Loeb, L. A. (1988). Fidelity of HIV-1 reverse transcriptase. *Science* **242**(4882), 1168-71.
- Prevec, L., Christie, B. S., Laurie, K. E., Bailey, M. M., Graham, F. L., and Rosenthal, K. L. (1991). Immune response to HIV-1 gag antigens induced by recombinant adenovirus vectors in mice and rhesus macaque monkeys. *J Acquir Immune Defic Syndr* **4**(6), 568-76.
- Reimann, K. A., Tenner-Racz, K., Racz, P., Montefiori, D. C., Yasutomi, Y., Lin, W., Ransil, B. J., and Letvin, N. L. (1994). Immunopathogenic events in acute infection of rhesus monkeys with simian immunodeficiency virus of macaques. *J Virol* **68**(4), 2362-70.
- Reitz, M. S., Jr., Wilson, C., Naugle, C., Gallo, R. C., and Robert-Guroff, M. (1988). Generation of a neutralization-resistant variant of HIV-1 is due to selection for a point mutation in the envelope gene. *Cell* **54**(1), 57-63.

- Rey-Cuille, M. A., Berthier, J. L., Bomsel-Demontoy, M. C., Chaduc, Y., Montagnier, L., Hovanessian, A. G., and Chakrabarti, L. A. (1998). Simian immunodeficiency virus replicates to high levels in sooty mangabeys without inducing disease. *J Virol* **72**(5), 3872-86.
- Riviere, Y., Robertson, M. N., and Buseyne, F. (1994). Cytotoxic T lymphocytes in human immunodeficiency virus infection: regulator genes. *Curr Top Microbiol Immunol* **189**, 65-74.
- Robert-Guroff, M., Brown, M., and Gallo, R. C. (1985). HTLV-III-neutralizing antibodies in patients with AIDS and AIDS-related complex. *Nature* **316**(6023), 72-4.
- Roberts, J. D., Bebenek, K., and Kunkel, T. A. (1988). The accuracy of reverse transcriptase from HIV-1. *Science* **242**(4882), 1171-3.
- Rowland-Jones, S., Sutton, J., Ariyoshi, K., Dong, T., Gotch, F., McAdam, S., Whitby, D., Sabally, S., Gallimore, A., Corrah, T., and et al. (1995). HIV-specific cytotoxic T-cells in HIV-exposed but uninfected Gambian women [published erratum appears in *Nat Med* 1995 Jun;1(6):598]. *Nat Med* **1**(1), 59-64.
- Rowland-Jones, S. L., Pinheiro, S., Kaul, R., Hansasuta, P., Gillespie, G., Dong, T., Plummer, F. A., Bwayo, J. B., Fidler, S., Weber, J., McMichael, A., and Appay, V. (2001). How important is the 'quality' of the cytotoxic T lymphocyte (CTL) response in protection against HIV infection? *Immunol Lett* **79**(1-2), 15-20.
- Ruprecht, R. M., Ferrantelli, F., Kitabwalla, M., Xu, W., and McClure, H. M. (2003). Antibody protection: passive immunization of neonates against oral AIDS virus challenge. *Vaccine* **21**(24), 3370-3.
- Rusche, J. R., Javaherian, K., McDanal, C., Petro, J., Lynn, D. L., Grimaila, R., Langlois, A., Gallo, R. C., Arthur, L. O., Fischinger, P. J., and et al. (1988). Antibodies that inhibit fusion of human immunodeficiency virus-infected cells bind a 24-amino acid sequence of the viral envelope, gp120. *Proc Natl Acad Sci U S A* **85**(9), 3198-202.
- Safrit, J. T., Andrews, C. A., Zhu, T., Ho, D. D., and Koup, R. A. (1994). Characterization of human immunodeficiency virus type 1-specific cytotoxic T lymphocyte clones isolated during acute seroconversion: recognition of autologous virus sequences within a conserved immunodominant epitope. *J Exp Med* **179**(2), 463-72.
- Saifuddin, M., Parker, C. J., Peeples, M. E., Gorny, M. K., Zolla-Pazner, S., Ghassemi, M., Rooney, I. A., Atkinson, J. P., and Spear, G. T. (1995). Role of virion-associated glycosylphosphatidylinositol-linked proteins CD55 and CD59 in complement resistance of cell line-derived and primary isolates of HIV-1. *J Exp Med* **182**(2), 501-9.
- Sambrook, J., and Gething, M. J. (1989). Protein structure. Chaperones, paperones. *Nature* **342**(6247), 224-5.
- Sarnagadharan, M. G., DeVico, A. L., Bruch, L., Schupbach, J., and Gallo, R. C. (1984). HTLV-III: the etiologic agent of AIDS. *Princess Takamatsu Symp* **15**, 301-8.
- Schellekens, P. T., Tersmette, M., Roos, M. T., Keet, R. P., de Wolf, F., Coutinho, R. A., and Miedema, F. (1992). Biphasic rate of CD4+ cell count decline during progression to AIDS correlates with HIV-1 phenotype. *Aids* **6**(7), 665-9.
- Schmitz, J. E., Kuroda, M. J., Santra, S., Sasseville, V. G., Simon, M. A., Lifton, M. A., Racz, P., Tenner-Racz, K., Dalesandro, M., Scallon, B. J., Ghayeb, J., Forman, M. A., Montefiori, D. C., Rieber, E. P., Letvin, N. L., and Reimann, K. A. (1999). Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. *Science* **283**(5403), 857-60.
- Sherman, M. P., de Noronha, C. M., Eckstein, L. A., Hataye, J., Mundt, P., Williams, S. A., Neidleman, J. A., Goldsmith, M. A., and Greene, W. C. (2003). Nuclear export of Vpr is required for efficient replication of human immunodeficiency virus type 1 in tissue macrophages. *J Virol* **77**(13), 7582-9.
- Shiver, J. W., Perry, H. C., Davies, M. E., Freed, D. C., and Liu, M. A. (1995). Cytotoxic T lymphocyte and helper T cell responses following HIV polynucleotide vaccination. *Ann N Y Acad Sci* **772**, 198-208.
- Siebelink, K. H., Tijhaar, E., Huisman, R. C., Huisman, W., de Ronde, A., Darby, I. H., Francis, M. J., Rimmelzwaan, G. F., and Osterhaus, A. D. (1995). Enhancement of feline immunodeficiency virus infection after immunization with envelope glycoprotein subunit vaccines. *J Virol* **69**(6), 3704-11.
- Silvestri, G., Sodora, D. L., Koup, R. A., Paiardini, M., O'Neil, S. P., McClure, H. M., Staprans, S. I., and Feinberg, M. B. (2003). Nonpathogenic SIV infection of sooty mangabeys is characterized by limited bystander immunopathology despite chronic high-level viremia. *Immunity* **18**(3), 441-52.
- Simon, M. A., Brodie, S. J., Sasseville, V. G., Chalifoux, L. V., Desrosiers, R. C., and Ringler, D. J. (1994). Immunopathogenesis of SIVmac. *Virus Res* **32**(2), 227-51.
- Sissons, J. G., and Oldstone, M. B. (1980). Killing of virus-infected cells: the role of antiviral antibody and complement in limiting virus infection. *J Infect Dis* **142**(3), 442-8.
- Sodroski, J., Goh, W. C., Rosen, C., Campbell, K., and Haseltine, W. A. (1986). Role of the HTLV-III/LAV envelope in syncytium formation and cytopathicity. *Nature* **322**(6078), 470-4.
- Spear, G. T., Sullivan, B. L., Landay, A. L., and Lint, T. F. (1990). Neutralization of human immunodeficiency virus type 1 by complement occurs by viral lysis. *J Virol* **64**(12), 5869-73.
- Stahl, R. E., Friedman-Kien, A., Dubin, R., Marmor, M., and Zolla-Pazner, S. (1982). Immunologic abnormalities in homosexual men. Relationship to Kaposi's sarcoma. *Am J Med* **73**(2), 171-8.

- Stevenson, M., Stanwick, T. L., Dempsey, M. P., and Lamonica, C. A. (1990). HIV-1 replication is controlled at the level of T cell activation and proviral integration. *Embo J* **9**(5), 1551-60.
- Stoiber, H., Clivio, A., and Dierich, M. P. (1997). Role of complement in HIV infection. *Annu Rev Immunol* **15**, 649-74.
- Stoll, M., Claes, C., Schulte, E., Graf von der Schulenburg, J. M., and Schmidt, R. E. (2002). Direct costs for the treatment of HIV-infection in a German cohort after the introduction of HAART. *Eur J Med Res* **7**(11), 463-71.
- Stott, E. J. (1991). Anti-cell antibody in macaques. *Nature* **353**(6343), 393.
- Sullivan, B. L., Knopoff, E. J., Saifuddin, M., Takefman, D. M., Saarloos, M. N., Sha, B. E., and Spear, G. T. (1996). Susceptibility of HIV-1 plasma virus to complement-mediated lysis. Evidence for a role in clearance of virus in vivo. *J Immunol* **157**(4), 1791-8.
- Taylor, J. M., Schwartz, K., and Detels, R. (1986). The time from infection with human immunodeficiency virus (HIV) to the onset of AIDS. *J Infect Dis* **154**(4), 694-7.
- UNAIDS/WHO (2002). AIDS epidemic update 2002.
- Veazey, R. S., Tham, I. C., Mansfield, K. G., DeMaria, M., Forand, A. E., Shvets, D. E., Chalifoux, L. V., Sehgal, P. K., and Lackner, A. A. (2000). Identifying the target cell in primary simian immunodeficiency virus (SIV) infection: highly activated memory CD4(+) T cells are rapidly eliminated in early SIV infection in vivo. *J Virol* **74**(1), 57-64.
- Venet, A., Bourgault, I., Aubertin, A. M., Kieny, M. P., and Levy, J. P. (1992). Cytotoxic T lymphocyte response against multiple simian immunodeficiency virusA (SIV) proteins in SIV-infected macaques. *J Immunol* **148**(9), 2899-908.
- Vogel, T., Kurth, R., and Norley, S. (1994). The majority of neutralizing Abs in HIV-1-infected patients recognize linear V3 loop sequences. Studies using HIV-1MN multiple antigenic peptides. *J Immunol* **153**(4), 1895-904.
- Vogel, T. U., Horton, H., Fuller, D. H., Carter, D. K., Vielhuber, K., O'Connor, D. H., Shipley, T., Fuller, J., Sutter, G., Erfle, V., Wilson, N., Picker, L. J., and Watkins, D. I. (2002). Differences between T cell epitopes recognized after immunization and after infection. *J Immunol* **169**(8), 4511-21.
- Volberding, P. A., Lagakos, S. W., Koch, M. A., Pettinelli, C., Myers, M. W., Booth, D. K., Balfour, H. H., Jr., Reichman, R. C., Bartlett, J. A., Hirsch, M. S., and et al. (1990). Zidovudine in asymptomatic human immunodeficiency virus infection. A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. The AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases. *N Engl J Med* **322**(14), 941-9.
- Wagner, R., Graf, M., Bieler, K., Wolf, H., Grunwald, T., Foley, P., and Uberla, K. (2000). Rev-independent expression of synthetic gag-pol genes of human immunodeficiency virus type 1 and simian immunodeficiency virus: implications for the safety of lentiviral vectors. *Hum Gene Ther* **11**(17), 2403-13.
- Waterhouse, N. J., and Trapani, J. A. (2002). CTL: Caspases Terminate Life, but that's not the whole story. *Tissue Antigens* **59**(3), 175-83.
- Weiss, R. A. (2002). HIV receptors and cellular tropism. *IUBMB Life* **53**(4-5), 201-5.
- Weiss, R. A., Clapham, P. R., Cheingsong-Popov, R., Dalgleish, A. G., Carne, C. A., Weller, I. V., and Tedder, R. S. (1985). Neutralization of human T-lymphotropic virus type III by sera of AIDS and AIDS-risk patients. *Nature* **316**(6023), 69-72.
- Yagita, M., Noda, I., Maehara, M., Fujieda, S., Inoue, Y., Hoshino, T., and Saksela, E. (1992). The presence of concanavalin-A(Con-A)-like molecules on natural-killer (NK)-sensitive target cells: their possible role in swainsonine-augmented human NK cytotoxicity. *Int J Cancer* **52**(4), 664-72.
- Yasutomi, Y., Reimann, K. A., Lord, C. I., Miller, M. D., and Letvin, N. L. (1993). Simian immunodeficiency virus-specific CD8+ lymphocyte response in acutely infected rhesus monkeys. *J Virol* **67**(3), 1707-11.
- Yasutomi, Y., Robinson, H. L., Lu, S., Mustafa, F., Lekutis, C., Arthos, J., Mullins, J. I., Voss, G., Manson, K., Wyand, M., and Letvin, N. L. (1996). Simian immunodeficiency virus-specific cytotoxic T-lymphocyte induction through DNA vaccination of rhesus monkeys. *J Virol* **70**(1), 678-81.
- Zhang, L., Yu, W., He, T., Yu, J., Caffrey, R. E., Dalmasso, E. A., Fu, S., Pham, T., Mei, J., Ho, J. J., Zhang, W., Lopez, P., and Ho, D. D. (2002). Contribution of human alpha-defensin 1, 2, and 3 to the anti-HIV-1 activity of CD8 antiviral factor. *Science* **298**(5595), 995-1000.
- Zhu, T., Corey, L., Hwangbo, Y., Lee, J. M., Learn, G. H., Mullins, J. I., and McElrath, M. J. (2003). Persistence of extraordinarily low levels of genetically homogeneous human immunodeficiency virus type 1 in exposed seronegative individuals. *J Virol* **77**(11), 6108-16.
- Zhu, T., Korber, B. T., Nahmias, A. J., Hooper, E., Sharp, P. M., and Ho, D. D. (1998). An African HIV-1 sequence from 1959 and implications for the origin of the epidemic. *Nature* **391**(6667), 594-7.